0000000000263630

AUTHOR

Veli-pekka Harjola

showing 4 related works from this author

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Survival and quality of life after early discharge in low-risk pulmonary embolism.

2020

IntroductionEarly discharge of patients with acute low-risk pulmonary embolism requires validation by prospective trials with clinical and quality-of-life outcomes.MethodsThe multinational Home Treatment of Patients with Low-Risk Pulmonary Embolism with the Oral Factor Xa Inhibitor Rivaroxaban (HoT-PE) single-arm management trial investigated early discharge followed by ambulatory treatment with rivaroxaban. The study was stopped for efficacy after the positive results of the predefined interim analysis at 50% of the planned population. The present analysis includes the entire trial population (576 patients). In addition to 3-month recurrence (primary outcome) and 1-year overall mortality, …

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPopulationPatient subgroups030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineSurveys and QuestionnairesMedicineHumansProspective StudieseducationEarly dischargeAgededucation.field_of_studyRivaroxabanbusiness.industrymedicine.diseaseInterim analysisPatient Discharge3. Good healthPulmonary embolism030228 respiratory systemAmbulatoryQuality of LifeFemalebusinessPulmonary Embolismmedicine.drugThe European respiratory journal
researchProduct

Pulmonary embolism location is associated with the co-existence of the deep venous thrombosis.

2019

Multiple studies have shown that in approximately half of individuals with pulmonary embolism (PE), the deep venous thrombosis (DVT) is not evident at the moment of PE diagnosis. The underlying factors and the origin of PE in these patients are not completely understood: missed DVT, embolization of DVT in its entirety, or de-novo PE being possible explanations. The aim of this study was to evaluate the differences in PE patient with or without co-existing DVT. Sixty-three consecutive PE patients were included. Whole leg bilateral Doppler compression ultrasound was performed to all patients. The PE location and extension, C-reactive protein, platelet count, hemostatic markers FV, FVIII, FXII…

AdultMalemedicine.medical_specialtyVEIN THROMBOSISmedicine.medical_treatment030204 cardiovascular system & hematologyFibrinogenPulmonary function testing03 medical and health sciencesTHROMBOEMBOLISM0302 clinical medicineInternal medicineSCOREmedicineFactor V LeidenFACTOR-V-LEIDENHumanscardiovascular diseasesEmbolizationProspective Studiescoagulationhemostatic markersProspective cohort studydeep venous thrombosisAgedRISKVenous ThrombosisHemostasisLegbusiness.industryUltrasonography DopplerHematologyGeneral MedicineNITRIC-OXIDE MEASUREMENTSMiddle Agedmedicine.disease3. Good healthPulmonary embolismVenous thrombosis3121 General medicine internal medicine and other clinical medicineHemostasisisolated pulmonary embolismCardiologyFemalebusinessPulmonary Embolism030215 immunologymedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct

Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction

2018

IF 16.834 (2017); International audience; BACKGROUND Vasopressor agents could have certain specific effects in patients with cardiogenic shock (CS) after myocardial infarction, which may influence outcome. Although norepinephrine and epinephrine are currently the most commonly used agents, no randomized trial has compared their effects, and intervention data are lacking. OBJECTIVES The goal of this paper was to compare in a prospective, double-blind, multicenter, randomized study, the efficacy and safety of epinephrine and norepinephrine in patients with CS after acute myocardial infarction. METHODS The primary efficacy outcome was cardiac index evolution, and the primary safety outcome was…

MaleInotropeILL PATIENTSCardiac index030204 cardiovascular system & hematologyLACTATE0302 clinical medicine[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesSUPPORTTISSUE OXYGENATIONVasoconstrictor AgentsProspective StudiesMyocardial infarctionCardiogenic shockcardiogenic shockMiddle Aged3. Good healthEpinephrineCardiologyHEARTFemaleTRIALFranceCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyShock Cardiogenicacute myocardial infarctionvasopressornorepinephrineEXTRACORPOREAL MEMBRANE-OXYGENATIONNorepinephrine (medication)03 medical and health sciencesDouble-Blind MethodInternal medicineHeart rateMANAGEMENTmedicineHumansepinephrineAgedbusiness.industrySeptic shockMORTALITYSEPTIC SHOCKHemodynamics030208 emergency & critical care medicinemedicine.disease3121 General medicine internal medicine and other clinical medicinebusiness
researchProduct